ZARONTIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZARONTIN (ZARONTIN).
Ethosuximide (Zarontin) suppresses paroxysmal 3 Hz spike-and-wave activity associated with absence seizures. The mechanism may involve inhibition of T-type calcium channels in thalamic neurons, reducing oscillatory burst firing.
| Metabolism | Ethosuximide is extensively metabolized in the liver, primarily via cytochrome P450 enzymes (CYP3A4) to inactive metabolites. Approximately 20% is excreted unchanged in urine. |
| Excretion | Renal: ~40% as unchanged drug; hepatic metabolism accounts for ~60% (primarily via CYP3A4, forming inactive metabolites); <1% fecal. |
| Half-life | 60 hours (range 40-70) in adults; 30-40 hours in children (due to higher clearance); clinical context: steady-state reached in ~10-14 days; may be reduced with enzyme-inducing co-medications. |
| Protein binding | ~90% bound to albumin; saturable at high concentrations, leading to increased free fraction. |
| Volume of Distribution | 0.5 L/kg; moderate distribution, primarily in total body water; crosses placenta and appears in breast milk (concentration ~50% of maternal serum). |
| Bioavailability | Oral: ~98% (near complete absorption); no parenteral formulation available. |
| Onset of Action | Oral: 2-4 hours (peak serum concentration); therapeutic effect (seizure control) may require 1-2 weeks of daily dosing. |
| Duration of Action | Oral: ~24 hours (serum levels maintained with once- or twice-daily dosing); clinical duration (seizure protection) extends throughout dosing interval due to long half-life. |
500 mg orally twice daily initially; may increase by 250 mg every 4-7 days. Maintenance: 1000-1500 mg/day in 2 divided doses; maximum 1500 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | No specific dose adjustment guidelines; caution with severe impairment (GFR <30 mL/min) due to possible accumulation; consider monitoring levels. |
| Liver impairment | No specific Child-Pugh based guidelines; use with caution in severe hepatic impairment. |
| Pediatric use | Age 3-6 years: 250 mg orally once daily initially; increase by 250 mg every 4-7 days. Maintenance: 500-750 mg/day in 2 divided doses. Age 6-16 years: 500 mg orally once daily initially; increase similarly. Maximum: 1000 mg/day. |
| Geriatric use | Start at lower end of dosing range (500 mg/day) due to age-related decline in renal function; monitor renal function and adjust accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZARONTIN (ZARONTIN).
| Breastfeeding | Ethosuximide (Zarontin) is excreted into breast milk. M/P ratio is approximately 0.9. Infant serum levels can reach therapeutic ranges, potentially causing sedation, poor sucking, or withdrawal. Risks vs benefits must be weighed; monitor infant for drowsiness and feeding difficulties. |
| Teratogenic Risk | First trimester: Increased risk of major congenital malformations, particularly neural tube defects, cleft lip/palate, and cardiac defects. Second and third trimesters: Risk of fetal hydantoin syndrome, including growth restriction, dysmorphic facial features, and neurodevelopmental impairment. Antiepileptic drugs in general increase risk; use lowest effective dose, consider folic acid supplementation. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to ethosuximide or any succinimide derivative."]
| Precautions | ["May cause blood dyscrasias including agranulocytosis, aplastic anemia, and pancytopenia; monitor CBC at baseline and periodically.","Systemic lupus erythematosus (SLE)-like syndrome has been reported.","Suicidal ideation and behavior; monitor for depression or mood changes.","May impair cognitive and motor function; caution with driving or operating machinery."] |
Loading safety data…
| Fetal Monitoring | Monitor serum ethosuximide levels every 4-6 weeks during pregnancy due to altered pharmacokinetics. Perform fetal ultrasound for anomaly detection at 18-20 weeks. Consider prenatal vitamin K supplementation in third trimester to prevent neonatal hemorrhagic disease. Postnatal: monitor infant for withdrawal symptoms, sedation, and poor feeding. |
| Fertility Effects | No well-documented adverse effects on fertility. Antiepileptic drugs may affect hormonal balance; data limited. Consult reproductive endocrinology if fertility issues arise. |